Prospective randomized clinical trial to evaluate the optimal dose of 131I for remnant ablation in patients with differentiated thyroid carcinoma

C Bal, AK Padhy, S Jana, GS Pant… - … International Journal of …, 1996 - Wiley Online Library
BACKGROUND Radioiodine has been used for more than a half‐century to ablate thyroid
remnants following thyroid surgery, but a single optimal dose has not been established. We …

Radioligand Therapy With 177Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis

…, RK Sahoo, SN Dwivedi, C Bal - American Journal of …, 2019 - Am Roentgen Ray Soc
OBJECTIVE. Several clinical studies have shown the efficacy of 177 Lu-labeled prostate-specific
membrane antigen (PSMA) radioligand therapy (RLT) for metastatic castration-resistant …

18F-FDOPA PET/CT for detection of recurrence in patients with glioma: prospective comparison with 18F-FDG PET/CT

…, R Kumar, DK Gupta, A Malhotra, C Bal - European journal of …, 2013 - Springer
Purpose Differentiation between recurrence and radiation necrosis in patients with glioma is
crucial, since the two entities have completely different management and prognosis. The …

177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment

…, NA Damle, RK Sahoo, A Seth, C Bal - European journal of …, 2017 - Springer
Purpose The purpose of this study was to evaluate the efficacy and safety of a novel
theranostic agent, 177 Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate …

[HTML][HTML] Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant prostate cancer patients

…, S Ballal, RK Sahoo, M Tripathi, A Seth, C Bal - Theranostics, 2020 - ncbi.nlm.nih.gov
Rationale: Despite the success of several standards of care treatment options in metastatic
castration-resistant prostate cancer (mCRPC), a significant number of patients attain …

Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu …

S Ballal, MP Yadav, C Bal, RK Sahoo… - European journal of …, 2020 - Springer
Purpose The objective of this study was to investigate and present the early results on the
efficacy, safety, and quality of life of 225 Ac-DOTATATE targeted alpha therapy (TAT) in …

The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and 99mTc …

NA Damle, C Bal, GP Bandopadhyaya, L Kumar… - Japanese journal of …, 2013 - Springer
Objectives We aimed to compare the role of 18 F-fluoride PET/CT, FDG PET/CT and 99m Tc-MDP
bone scans in the detection of bone metastases in patients with lung, breast and …

Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma

JA Sosa, R Elisei, B Jarzab, J Balkissoon, S Lu, C Bal… - Thyroid, 2014 - liebertpub.com
Background: Anaplastic thyroid cancer (ATC), a rare highly vascularized tumor, has a
dismal outcome. We conducted an open-label study of doublet carboplatin/paclitaxel …

Biodistribution, pharmacokinetics, dosimetry of [68Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [18F]F-FDG PET/CT in patients with various cancers

…, M Tripathi, ST ArunRaj, S Sarswat, C Bal - European journal of …, 2021 - Springer
Purpose [ 68 Ga]Ga-labeled fibroblast activation protein inhibitors ([ 68 Ga]Ga-FAPi) have
shown promising preclinical and clinical results in PET imaging. The present study aimed to …

A theranostic approach of [68Ga]Ga-DOTA.SA.FAPi PET/CT-guided [177Lu]Lu-DOTA.SA.FAPi radionuclide therapy in an end-stage breast cancer patient: new …

…, M Tripathi, S Mallick, ST ArunRaj, C Bal - European journal of …, 2021 - Springer
A 31-year-young female was diagnosed with breast cancer in September 2019. The
histopathology revealed atypical cells arranged cords and tubules in the fibrotic stroma suggestive …